We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-14.06%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$18.1M
Cap. Flow
+$21.8M
Cap. Flow %
12.11%
Top 10 Hldgs %
59.22%
Holding
45
New
6
Increased
14
Reduced
14
Closed
11

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$12.1M
2
UTHR icon
United Therapeutics
UTHR
+$10M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$7.87M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$4.82M
5
GH icon
Guardant Health
GH
+$3.67M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$5.29M
2
BMY icon
Bristol-Myers Squibb
BMY
+$4.96M
3
ZBH icon
Zimmer Biomet
ZBH
+$4.87M
4
QTTB icon
Q32 Bio
QTTB
+$4.07M
5
INDP icon
Indaptus Therapeutics
INDP
+$3.54M

Sector Composition

Rank Sector Weight
1 Healthcare 97.43%
2 Industrials 2.03%
3 Miscellaneous 0.55%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
$2.32M 1.29%
244,604
-52,168
-18% -$411K
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
$2.31M 1.28%
587,626
+137,626
+31% +$1.11M
PSNL icon
28
Personalis
PSNL
$1.82B
$1.69M 0.94%
115,214
+58,768
+104% +$1.11M
CI icon
29
Cigna
CI
$73.7B
$1.67M 0.93%
11,000
-20,227
-65% -$3.29M
MTEM
30
DELISTED
Molecular Templates, Inc.
MTEM
$1.47M 0.82%
14,866
+1,687
+13% +$157K
RETA
31
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$988K 0.55%
+12,300
New +$1.04M
UROV
32
DELISTED
Urovant Sciences Ltd.
UROV
$972K 0.54%
102,657
-39,963
-28% -$347K
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$924K 0.51%
59,168
-7,872
-12% -$151K
TPST icon
34
Tempest Therapeutics
TPST
$17.5M
$370K 0.21%
267
-112
-30% -$181K
EFOR
35
Everforth Inc
EFOR
$1.31B
– –
-30,000
Closed -$1.82M
ASMB icon
36
Assembly Biosciences
ASMB
$694M
– –
-16,667
Closed -$2.7M
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
– –
-17,948
Closed -$603K
EOLS icon
38
Evolus
EOLS
$587M
– –
-112,590
Closed -$1.65M
EXAS
39
PUT
DELISTED
Exact Sciences
EXAS
– –
-14,100
Closed -$1.66M
INDP icon
40
Indaptus Therapeutics
INDP
$152M
– –
-364
Closed -$3.54M
KZR
41
DELISTED
Kezar Life Sciences
KZR
– –
-3,422
Closed -$264K
MODV
42
DELISTED
ModivCare
MODV
– –
-14,677
Closed -$842K
NGNE icon
43
Neurogene
NGNE
$732M
– –
-182
Closed -$9K
NVRO
44
DELISTED
NEVRO CORP.
NVRO
– –
-11,000
Closed -$713K
WCG
45
DELISTED
Wellcare Health Plans, Inc.
WCG
– –
-6,500
Closed -$1.85M
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2019 Portfolio in Review

As of Q3 2019, Prosight Management held 45 positions worth $180M, down 9.1% from $198M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management deployed $21.8M of net new capital in Q3 2019, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was MeiraGTx Holdings: 338,096 shares worth $5.39M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $5.29M trimmed.

  • Prosight Management's largest Q3 2019 buy was MeiraGTx Holdings: 338,096 shares worth $5.39M.
  • Prosight Management added most to uniQure in Q3 2019, an estimated $12.1M increase.
  • Prosight Management's biggest Q3 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $5.29M.
  • Prosight Management fully exited Indaptus Therapeutics in Q3 2019, selling an estimated $3.54M.
  • Prosight Management's ten largest holdings make up 59% of its $180M portfolio in Q3 2019.
  • Prosight Management opened 6 new positions and closed 11 in Q3 2019.
  • Prosight Management's portfolio value fell 9.1% quarter-over-quarter to $180M.

Based on Prosight Management's 13F filing for Q3 2019, filed 14 Nov 2019.